KBC Securities - Holdings Report - December 2025 Discussing our recent target price increase on Whitestone and our rating change on Brederode

Report

KBC Securities

Livio Luyten

Holdings Report - December 2025 Discussing our recent target price increase on Whitestone and our rating change on Brederode

We're excited to share our latest views on two compelling investment companies within the holdings universe. Brederode's robust Q3 operational momentum and wide ~28% NAV discount prompt a cautious upgrade to Accumulate (€125 TP maintained). Whitestone's €70m capital raise at NAV premium, backed by strong shareholders and GFI's gold tailwinds, is a positive catalyst that led us to raise our TP to €18.0 (from €15.0). Click below to read the full updates.

06/01/2026 1 EN

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Livio Luyten

Other Reports from KBC Securities

Guy Sips ... (+5)

Guy Sips
Hilde Van Boxstael
Kristof Samoy
Thomas Couvreur
Wim Lewi

Morning Notes : ASRNL NA, BAR BB, CMBT BB

: ASRNL NA, BAR BB, CMBT BB

2h / 49m 2h / 49m 1 EN

Kristof Samoy

Kristof Samoy

CMB.Tech Intelligent asset disposal showcasing skill to time the cycle

CMBT struck the iron while it was hot and in line with its fleet rejuvenation strategy has been offloading 6 older VLCCs and two Capesizes. We estimate the aggregate disposal value at $500m. We expect the block sale to have occurred at firm prices absent discount -perhaps even exceeding our and Clarksons fair market values- considering the booming VLCC rates witnessed in 4Q25. Market rates in this segment were well above $100.000/day at numerous times past months. Half of the capital gain of $269m to be posted in 1Q26 (so $135m) will be distributed to shareholders while the remainder will be u...

3h / 7m 3h / 7m 1 EN

Jacob Mekhael

Jacob Mekhael

mdxhealth Collaboration with Oxford could further validate GPS in prostate cancer

Yesterday before US market opens, mdxhealth announced the next major phase of its collaboration with the University of Oxford: the initiation of Genomic Prostate Score (GPS) testing in the landmark UK ProtecT trial (Prostate Testing for Cancer and Treatment). This study is designed to establish GPS as the first genomic classifier supported by randomised clinical trial evidence in an Active Surveillance cohort, further validating the clinical utility of GPS in predicting prostate cancer progression and long-term treatment outcomes. According to management, data publication is expected in 2026/2...

January 7, 2026 January 7, 2026 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Holdings Report - December 2025 Discussing our recent target price increase on Whitestone and our rating change on Brederode

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : ASRNL NA, BAR BB, CMBT BB

CMB.Tech Intelligent asset disposal showcasing skill to time the cycle

mdxhealth Collaboration with Oxford could further validate GPS in prostate cancer

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe